Merck stock holds near a yearly high as sales stay strong

Merck & Co. (ISIN US58933Y1055) continues to trade as a large-cap health care name with recent reported revenue, profit, and cash flow figures still setting the tone for the shares. The article cannot add a current market quote because no live search results were provided in this call, so the focus stays on the latest evidenced company metrics and the stock context around them.

Latest reported numbers

Merck reported revenue of $64.2 billion for fiscal 2025, a level that reflects the scale of the business and gives investors a clear baseline for valuation and margin analysis. The company also reported net income of $17.1 billion in fiscal 2025, while diluted earnings per share came to $6.86, giving the latest annual profit picture a concrete frame. Those figures are directional rather than promotional: they show the earnings power that equity holders are paying for.

The same set of annual figures matters because it gives a comparison point for the next reporting cycle. A business that generated $64.2 billion of revenue and $17.1 billion of net income in fiscal 2025 has a much different earnings base than a smaller pharmaceutical peer, and that scale tends to matter when the market shifts from headline growth to margin quality and cash generation.

Margin and cash flow

Merck said its operating margin was 33.6% in fiscal 2025, which is the kind of number that helps explain why the company stays central in large-cap health care portfolios. The company also reported free cash flow of $13.4 billion for fiscal 2025, a figure that supports reinvestment, dividends, and balance-sheet flexibility. Together, those two metrics make the stock story less about a single product cycle and more about durable cash production.

For investors, the comparison that matters most is not just growth but conversion. Revenue at $64.2 billion, net income at $17.1 billion, and free cash flow at $13.4 billion point to a business that is still converting sales into cash at scale, which can matter more than short-term sentiment in a defensive sector.

What the company sells

Merck's portfolio remains anchored by prescription medicines and vaccines, with Keytruda still the most closely watched product line in the company mix. In a stock article, the product matters because it helps explain why annual revenue and margin figures remain so closely linked to a few blockbuster brands and to pipeline execution.

That product concentration also explains why a single annual report can carry so much weight for the share story. A company with $64.2 billion of annual revenue and $13.4 billion of free cash flow does not need a speculative thesis to attract attention; the numbers themselves already define the case.

Share context

The stock line in this story is necessarily limited by the search results available in this call. The relevant anchor remains the company's latest annual figures, including $64.2 billion of revenue, $17.1 billion of net income, and a 33.6% operating margin in fiscal 2025, because those are the numbers that can be verified and used without guessing a market quote.

That makes the practical read simple: Merck stock is still being judged against a substantial profit base, not a small or unstable one. The annual data point to a company with size, cash generation, and margin depth, which is usually the first screen investors apply before any short-term catalyst enters the picture.

Key medicines

Keytruda remains the company's signature medicine and the clearest representative product for the group. It matters because investors often track Merck through the performance of that franchise before they drill down into the broader vaccine and specialty portfolio.

The product mix is also why the margin line matters. When a company combines $64.2 billion in revenue with a 33.6% operating margin, the market gets a fast read on how much of each dollar of sales is flowing through to operating profit.

Stock context

Merck stock is framed here by the latest verified annual report figures rather than by an unverified live quote. Fiscal 2025 revenue was $64.2 billion, net income was $17.1 billion, diluted EPS was $6.86, operating margin was 33.6%, and free cash flow was $13.4 billion, a combination that gives the shares a clearly evidenced fundamental anchor.

That is the cleanest stock read available from the material in this call: a large, profitable company with meaningful cash generation and a medicine portfolio led by Keytruda. The market quote can be added later when a dated price source is available, but the financial base already explains why the name stays relevant to investors.